A pair of camel-derived nanoantibodies targeting the pathogenic factors of acute hepatopancreatic necrosis of shrimp and preparation method thereof
By constructing and screening high-affinity nano-antibodies and combining colloidal gold technology, the problems of low sensitivity and complex operation in the detection method of parahemolytic Vibrio are solved, and the rapid detection of parahemolytic Vibrio in shrimp farming is achieved, reducing costs and operational complexity.
Patent Information
- Application Number
- CN202410970798.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-07-19
AI Technical Summary
The existing Vibrio parahaemolytic detection methods have problems such as low sensitivity, long reaction time, complex operation and high cost, and it is difficult to conduct continuous monitoring during shrimp farming, especially the molecular weight of traditional antibodies against pirA and pirB genes is relatively large. Limits its application.
By constructing recombinant plasmids of pirA and pirB, high-affinity alpaca nano-antibody is produced using the prokaryotic expression system, and nano-antibody with different CDR3 regions is screened in combination with phage display technology, and fast and convenient detection methods are developed in combination with colloidal gold technology.
It realizes rapid and highly sensitive detection of Vibrio parahaemolyticus, reduces production and R&D costs, simplifies the operation process, and is suitable for the prevention and monitoring of epidemics in shrimp farming.
Smart Images

Figure CN118515754B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of Vibrio detection, and in particular to a pair of camel-derived nano antibodies targeting pathogenic factors of acute hepatopancreatic necrosis of shrimp and a preparation method thereof. Background Art
[0002] Acute hepatopancreatic necrosis disease (AHPND) is one of the major diseases affecting shrimp farming. Due to its high toxicity, the mortality rate of diseased shrimp can reach 70% to 100%, which has had a serious impact on the economy of the shrimp farming industry worldwide. The pathogenic bacteria of AHPND are Vibrio bacteria. Studies have shown that specific virulent strains of Vibrio parahaemolyticus (Vp AHPND ) can cause AHPND because it carries the pVA1 plasmid (69 kbp) that encodes pirA and pirB proteins. With the increasing demand for disease detection in shrimp farms and customs in my country, the development of early, rapid and accurate methods for detecting Vibrio parahaemolyticus for non-diagnostic and therapeutic purposes is of great significance for disease prevention in shrimp farming.
[0003] At present, there are many detection methods for Vibrio parahaemolyticus, including traditional detection methods of Vibrio parahaemolyticus, including histopathology, polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RT-PCR), monoclonal antibody assay, biosensor and enzyme-linked immunosorbent assay (ELISA), etc. These molecular detection technologies have high sensitivity and reliability, but they require long reaction time, complex instruments and professional operation, and the price is too high, so they cannot be continuously monitored during shrimp farming.
[0004] In recent years, antibody-based detection has provided an attractive alternative. However, the research on antibodies against the pirA and pirB genes of Vibrio parahaemolyticus is mainly based on traditional polyclonal and monoclonal antibodies. Traditional antibodies have a large molecular weight and are limited in application. Nanobodies are the smallest antibody units known to have antigen recognition activity. The CDR3 region of nanobodies enables them to recognize hidden areas of antigens. They have advantages that traditional antibodies do not have, such as small size, strong penetration, and easy modification. Therefore, it is necessary to focus on finding high-affinity anti-pirA and pirB nanobodies and conduct related research.
[0005] Colloidal gold immunochromatographic test strips are one of the most widely used methods for rapid pathogen detection. The reaction principle of this method is the interaction between antigen and antibody, and it combines immunochromatography and colloidal gold labeling. Compared with traditional immunological methods, this method has the advantages of simple operation, fast speed, no equipment and experience required, etc. Therefore, it is necessary to study how to combine nanoantibodies with colloidal gold technology, and further develop fast, convenient and highly sensitive colloidal gold test strips for pathogen detection, so as to solve the effective prevention and efficient monitoring of diseases in shrimp farming production. Summary of the invention
[0006] The purpose of the present invention is to find high-affinity anti-pirA and pirB nanobodies to solve the technical problem:
[0007] The first aspect of the present invention provides a method for preparing or screening nano antibodies for detecting Vibrio parahaemolyticus, comprising the following steps: step A: expression of pirA antigen protein or pirB antigen protein, comprising: constructing a pirA recombinant plasmid or a pirB recombinant plasmid, inducing expression of the constructed pirA recombinant plasmid or the pirB recombinant plasmid through prokaryotes and purifying to obtain the pirA antigen protein or the pirB antigen protein; step B: construction of a camel-derived natural library; step C: performing auxiliary phage rescue and purification on the constructed camel-derived natural library to obtain a phage library and detect its titer; step D: performing two, three, four or five rounds of panning on the phage library to obtain a final eluate; step E: using the final eluate to prepare a supernatant for phage-ELISA identification and sequencing, and screening pirA nano antibodies or pirB nano antibodies with different CDR3 region sequences according to the sequencing results.
[0008] A second aspect of the present invention provides a nanobody obtained by the above-mentioned antibody preparation or screening method, characterized in that the amino acid sequence of the nanobody is as shown in SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19 or SEQ ID NO.20.
[0009] The third aspect of the present invention provides a nanobody for detecting Vibrio parahaemolyticus, the nanobody being identical to or having at least 80%, 85%, 90%, 95%, 98%, or 99% homology with any one of the following amino acid sequences: SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, or SEQID NO.20.
[0010] Furthermore, Vibrio parahaemolyticus is a specific virulent strain Vp AHPND .
[0011] Furthermore, the nanoantibodies SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10 are pirA protein antibodies, and SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, and SEQ ID NO.20 are pirB protein antibodies.
[0012] Furthermore, the nanoantibody is of alpaca or camel origin.
[0013] A fourth aspect of the present invention provides the use of the above-mentioned nanoantibody in the detection of Vibrio parahaemolyticus for non-diagnostic purposes.
[0014] A fifth aspect of the present invention provides a Vibrio parahaemolyticus detection product comprising the above-mentioned nanobody.
[0015] Furthermore, the Vibrio parahaemolyticus detection product includes reagents, test strips or test kits, and the test strips include immunochromatographic test strips prepared using any one of the labeling technologies of colloidal gold labeling, colloidal carbon labeling, fluorescent microsphere labeling, and nanoparticle labeling.
[0016] Furthermore, the Vibrio parahaemolyticus detection product includes a first antibody combination and a second antibody combination; the first antibody combination is used to specifically identify the pirA antigen protein, including: a first gold-labeled antibody with an amino acid sequence of SEQ ID NO.9, a first T-line antibody with an amino acid sequence of SEQ ID NO.8, and an anti-his tag antibody as a first C-line antibody; the second antibody combination is used to specifically identify the pirB antigen protein, including: a rabbit polyclonal antibody as a second gold-labeled antibody, a second T-line antibody with an amino acid sequence of SEQ ID NO.11, and a goat anti-rabbit antibody as a second C-line antibody.
[0017] The present invention utilizes phage display technology (phage-ELISA) to screen anti-pirA and pirB nanoantibodies from a natural phage library derived from alpacas, and adopts a prokaryotic expression system for production, thereby finding high-affinity anti-pirA and pirB nanoantibodies and reducing production and research and development costs.
[0018] In addition, the detection product of the present invention utilizes the principle of interaction between antigen and antibody, combines immunochromatography and colloidal gold labeling and other technologies, and compared with traditional immunological methods, this method has the advantages of simple operation, fast speed, no need for equipment and experience, etc. And by combining nano-antibodies with colloidal gold technology, a fast, convenient and highly sensitive colloidal gold test strip is further developed, which can detect whether aquatic animals such as shrimps and aquaculture waters are infected with Vibrio parahaemolyticus, whether aquaculture feeds are contaminated with Vibrio parahaemolyticus, etc., to achieve rapid detection of Vibrio parahaemolyticus, which is conducive to better effective prevention and efficient monitoring of epidemic diseases in shrimp farming production. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The above content and the following specific embodiments of the present invention will be better understood when read in conjunction with the accompanying drawings. It should be noted that the accompanying drawings are only examples of the technical solutions claimed for protection.
[0020] Figure 1 This is an agarose gel electrophoresis diagram of the first round of PCR amplification products in Example 1 of the present invention (M is DL1000 marker; lanes 1 and 2 are PCR amplification bands of pirA and pirB genes, respectively);
[0021] Figure 2 This is an agarose gel electrophoresis diagram of the second round of PCR amplification products in Example 1 of the present invention (M is DL1000 marker; lanes 1 and 2 are pirA and pirB bacterial solution PCR amplification bands, respectively);
[0022] Figure 3This is a diagram of the prokaryotic expression and purification of the pirA protein in Example 1 of the present invention (M: marker; 1: pirA first culture solution; 2: pirA first induced solution; 3: pirA second resuspension solution; 4: pirA first supernatant solution; 5: pirA loading solution FT; 6: pirA 40 mM imidazole washed protein; 7: pirA protein);
[0023] Figure 4 This is a diagram of the prokaryotic expression and purification of the pirB protein in Example 1 of the present invention (M: marker; 1: pirB first culture solution; 2: pirB first induced solution; 3: pirB second resuspension solution; 4: pirB first supernatant solution; 5: pirB loading solution FT; 6: pirB 40 mM imidazole washed protein; 7: pirB protein);
[0024] Figure 5 The BCA protein concentration determination curve of the pirA antigen protein and the pirB antigen protein in Example 1 of the present invention (the horizontal axis is the standard BSA concentration, in mg / mL; the vertical axis is OD 562 nm absorbance value at );
[0025] Figure 6 This is the SDS-PAGE electrophoresis diagram of the purified pirA and pirB proteins in Example 1 of the present invention (M: marker; 1: purified pirA protein (13 kDa); 2: purified pirB protein (52 kDa));
[0026] Figure 7 This is a Western blot identification diagram of the purified pirA and pirB proteins in Example 1 of the present invention (M: marker; 1: purified pirA protein (13 kDa); 2: purified pirB protein (52 kDa));
[0027] Figure 8 This is a graph of the binding of 96 phage monoclones to the pirA antigen identified by phage-ELISA in Example 1 of the present invention (the horizontal axis is the pirA phage monoclone number, and the vertical axis is the pirA phage monoclone at OD 460 nm absorbance value);
[0028] Fig. 9 This is a graph of the binding of 96 phage monoclones to the pirB antigen identified by phage-ELISA in Example 2 of the present invention (the horizontal axis is the pirB phage monoclone number, and the vertical axis is the pirB phage monoclone at OD 460 nm absorbance value at );
[0029] Fig.10This is a diagram showing the alignment results of 13 positive clone sequences in Example 3 of the present invention (VHH-A1~A3 are pirA positive clone sequences, and VHH-B1~B10 are pirB positive clone sequences);
[0030] Fig.11 This is the SDS-PAGE electrophoresis diagram of the purified VHH nanobody protein in Example 3 of the present invention (M: marker; A1~A2: VHH-A1~A2 nanobody protein; B1~B10: VHH-B1~B10 nanobody protein);
[0031] Fig.12 The BCA protein concentration determination curve of the VHH nanobody in Example 3 of the present invention (the horizontal axis is the standard BSA concentration, in mg / mL; the vertical axis is OD 562 nm absorbance value at );
[0032] Fig.13 This is a Western blot identification diagram of the purified VHH nanobody protein in Example 3 of the present invention (M: protein marker; other lanes: corresponding to VHH-A1, A2, VHH-B1~B10 nanobody proteins);
[0033] Fig.14a This is a graph showing the affinity validation of the VHH-A1 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-A1 antibody, in log 10 (ng / μL));
[0034] Fig.14b This is the affinity verification diagram of Anti-pirA-pAb nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of Anti-pirA-pAb antibody, in log 10 (ng / μL));
[0035] Fig.15a This is a graph showing the affinity validation of the VHH-B1 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B1 antibody, in log 10 (ng / μL));
[0036] Fig.15b This is a graph showing the affinity validation of the VHH-B2 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B2 antibody, in log 10 (ng / μL));
[0037] Fig.15c This is a graph showing the affinity validation of the VHH-B3 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B3 antibody, in log 10 (ng / μL));
[0038] Fig.15d This is a graph showing the affinity validation of the VHH-B4 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B4 antibody, in log 10 (ng / μL));
[0039] Fig.15e This is a graph showing the affinity validation of the VHH-B5 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B5 antibody, in log 10 (ng / μL));
[0040] Fig.15f This is a graph showing the affinity validation of the VHH-B6 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B6 antibody, in log 10 (ng / μL));
[0041] Figure 15g This is a graph showing the affinity validation of the VHH-B7 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B7 antibody, in log 10 (ng / μL));
[0042] Fig.15h This is a graph showing the affinity validation of the VHH-B8 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B8 antibody, in log 10 (ng / μL));
[0043] Fig.15i This is a graph showing the affinity validation of the VHH-B9 nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of VHH-B9 antibody, in log 10 (ng / μL));
[0044] Fig.15j This is a graph showing the affinity verification of the VHH-B10 nanobody in Example 3 of the present invention (the ordinate is OD 450nmThe absorbance value at the abscissa is the concentration of VHH-B10 antibody, in log 10 (ng / μL));
[0045] Figure 15k This is the affinity verification diagram of Anti-pirB-pAb nanobody in Example 3 of the present invention (the ordinate is OD 450nm The absorbance value at the abscissa is the concentration of Anti-pirB-pAb antibody, in log 10 (ng / μL));
[0046] Fig.16 The binding of the VHH nanobody corresponding to pirA in Example 3 of the present invention to colloidal gold (A is the binding before centrifugation, B is the centrifugation re-dissolution; A1 is the VHH-A1 nanobody, A2 is the VHH-A2 nanobody, and R-pAb-A is a rabbit polyclonal antibody nanobody);
[0047] Fig.17 The binding of the VHH nanobody corresponding to pirB in Example 3 of the present invention to colloidal gold (A is the binding before centrifugation, B is the centrifugation re-dissolution; B1 to B10 are VHH-B1 to B10 nanobodies, respectively, and R-pAb-B is a rabbit polyclonal antibody nanobody);
[0048] Fig.18 The structure diagram of the test strip in Example 4 of the present invention (wherein 1 is the sample pad; 2 is the gold label pad; 3 is the NC membrane; 4 is the absorbent pad; 5 is the T-line antibody; 6 is the C-line antibody);
[0049] Fig.19 It is a colloidal gold test strip test result diagram of pirA antigen in Test Example 1 of the present invention (No. 1: VHH-A1 is the gold-labeled antibody, VHH-A2 is the T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 2: VHH-A1 is the gold-labeled antibody, the rabbit polyclonal antibody is the T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 3: VHH-A2 is the gold-labeled antibody, the rabbit polyclonal antibody is the T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 4: VHH-A2 is the gold-labeled antibody, VHH-A1 is the T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 5: the rabbit polyclonal antibody is the gold-labeled antibody, VHH-A1 is the T-line antibody, and the goat anti-rabbit is used as the C-line antibody; No. 6: the rabbit polyclonal antibody is the gold-labeled antibody, VHH-A2 is the T-line antibody, and the goat anti-rabbit is used as the C-line antibody);
[0050] Fig. 20The sensitivity test result diagram of the pirA antigen colloidal gold test strip in Test Example 2 of the present invention (wherein, VHH-A2 is the gold-labeled antibody, VHH-A1 is the T-line antibody, the anti-his tag antibody is the C-line antibody, and 1-6 represent sample concentrations of 1 mg / mL, 0.5 mg / mL, 0.25 mg / mL, 125 μg / mL, 62.5 μg / mL, and 0, respectively);
[0051] Fig.21 This is a graph showing the specificity test results of the pirA antigen colloidal gold test strip in Test Example 3 of the present invention (wherein VHH-A2 is used as the gold-labeled antibody, VHH-A1 is the T-line antibody, the anti-his tag antibody is used as the C-line antibody, and 1-5 represent pirA, MBP, GST, SWP1, and VP28 antigen proteins at a concentration of 1 mg / mL, respectively);
[0052] Fig. 22 4: VHH-B8 is a gold-labeled antibody, VHH-B1 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 5: rabbit polyclonal antibody is a gold-labeled antibody, VHH-B1 is a T-line antibody, and the goat anti-rabbit antibody is used as the C-line antibody; No. 6: VHH-B1 is a gold-labeled antibody, VHH-B2 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 7: VHH-B1 is a gold-labeled antibody, VHH-B2 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 8: VHH-B8 is a gold-labeled antibody, VHH-B1 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 9: VHH-B1 is a gold-labeled antibody, VHH-B2 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 10: VHH-B1 is a gold-labeled antibody, VHH-B2 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 11: VHH-B1 is a gold-labeled antibody, VHH-B2 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 12: VHH-B1 is a gold-labeled antibody, VHH-B2 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 13: VHH-B1 is a gold-labeled antibody, VHH-B2 is a T-line antibody, and the anti-his tag antibody is used as the C-line antibody; No. 14: VHH-B1 is a gold-labeled No. 7: VHH-B8 is the gold-labeled antibody, VHH-B2 is the T-line antibody, and the anti-his tag antibody is the C-line antibody; No. 8: rabbit polyclonal antibody is the gold-labeled antibody, VHH-B2 is the T-line antibody, and goat anti-rabbit is the C-line antibody; No. 9: VHH-B1 is the gold-labeled antibody, rabbit polyclonal antibody is the T-line antibody, and the anti-his tag antibody is the C-line antibody; No. 10: VHH-B2 is the gold-labeled antibody, rabbit polyclonal antibody is the T-line antibody, and the anti-his tag antibody is the C-line antibody; No. 11: VHH-B3 is the gold-labeled antibody, rabbit polyclonal antibody is the T-line antibody, and the anti-his tag antibody is the C-line antibody; No. 12: VHH-B6 is the gold-labeled antibody, rabbit polyclonal antibody is the T-line antibody, and the anti-his tag antibody is the C-line antibody; No. 13: VHH-B8 is the gold-labeled antibody, rabbit polyclonal antibody is the T-line antibody, and the anti-his tag antibody is the C-line antibody);
[0053] Fig.23The sensitivity test result diagram of the pirB antigen colloidal gold test strip in Test Example 5 of the present invention (wherein, rabbit polyclonal antibody is the gold-labeled antibody, VHH-B1 is the T-line antibody, goat anti-rabbit is the C-line antibody, and 1-7 represent sample concentrations of 1 mg / mL, 0.5 mg / mL, 0.25 mg / mL, 125 μg / mL, 62.5 μg / mL, 31.25 μg / mL, and 0, respectively);
[0054] Fig.24 This is a graph showing the specificity test results of the pirB antigen colloidal gold test strip in Test Example 6 of the present invention (wherein, rabbit polyclonal antibody is the gold-labeled antibody, VHH-B1 is the T-line antibody, goat anti-rabbit is the C-line antibody, and 1-5 represent pirA, MBP, GST, SWP1, and VP28 antigen proteins at a concentration of 1 mg / mL, respectively). DETAILED DESCRIPTION
[0055] The detailed features and advantages of the present invention are described in detail in the specific implementation modes below, and the contents are sufficient to enable any person skilled in the art to understand the technical contents of the present invention and implement them accordingly. Moreover, according to the description, claims and drawings disclosed in this specification, those skilled in the art can easily understand the relevant objects and advantages of the present invention.
[0056] It should be noted that in this specification, similar reference numerals and letters denote similar items in the following drawings, and therefore, once an item is defined in one drawing, it does not need to be further defined and explained in the subsequent drawings.
[0057] In order to make the purpose, technical scheme and advantages of the present invention clearer, the embodiments of the present invention will be further described in detail below with reference to the accompanying drawings. The experimental methods described in the embodiments of the present invention are conventional methods unless otherwise specified, and the materials, reagents, etc. used in the following embodiments can be obtained from commercial channels unless otherwise specified.
[0058] (1) Source of sample materials
[0059] Alpaca natural library: purchased from Shenzhen Kangti Life Science Technology Co., Ltd.
[0060] Upstream and downstream primer synthesis and sequencing: carried out by Sangon Biotech (Shanghai) Co., Ltd., hereinafter referred to as Sangon.
[0061] (2) Sources of reagents and consumables
[0062] Table 1 Sources and item numbers of reagents and consumables required for the experiment
[0063] name Manufacturer Part Number High-fidelity polymerase Novozymes P515-01 pEASY®-Blunt E1 Expression Kit All gold CE111 BL21 (DE3) competent cells Tiangen CB105 Agarose Qingke Biotechnology TSJ001 Taq enzyme Novozymes P112-01 Gelred Nucleic Acid Stains Novozymes GR501-01 Agarose DNA Recovery Kit Tiangen DP209 Plasmid Extraction Kit Tiangen DP103 DL1000 DNA Marker Takara 3591A DL2000 DNA Marker Takara 3427A Agar powder Solebao 9002-18-0 Ampicillin Shanghai Bioengineering AB0064 Tryptone Oxoid LP004 Yeast powder Oxoid LP0021B Ni-NTA Cytiva 17531802 10× DNA loading buffer Novozymes P022-01 5× protein loading buffer (containing DTT, referred to as 5× loading buffer) Solebao P1040 Prestained protein marker Thermo Fisher LC5615 Non-prestained protein markers Thermo Fisher 26610 SDS-PAGE gel fast stain absci Ab.001.10 Sodium chloride Shanghai Bioengineering A501218-0001 20×PBS Solebao P1032 Imidazole Shanghai Bioengineering A506644-0100 Tween20 Shanghai Bioengineering A600560-0500 Methanol Shanghai Test 10014108 Glycine Shanghai Bioengineering A610235-0500 Bovine serum albumin (BSA) Solebao A8010 PD-10 Desalting Column Cytiva 17085101 Ultrafiltration tube Merck Millipore UFC901096 BCA Kit Blue Sky P0012S Mouse anti-6 × His monoclonal antibody (mouse monoclonal antibody) Shanghai Bioengineering D191001-0025 Goat anti-mouse HRP (goat anti-mouse) Shanghai Bioengineering D191001-0025 Tris Shanghai Bioengineering A100193-0005 SDS Shanghai Bioengineering C520001-0500 HCl Shanghai Test 10011060 Skim milk powder Yamei PS112 Isopropylthio-β-D-galactoside Solebao I8070 Omni-Easy™ One-Step PAGE Gel Rapid Preparation Kit Yamei PG213 / PG214 Omni-ECL™ Basic Chemiluminescent Detection Kit (Picogram Level) Yamei SQ202 Immunotube Baroque 12-1275 Immunotube cap Baroque 12-1299 glucose Shanghai Bioengineering A501991-0500 PEG8000 Shanghai Bioengineering A100159-0500 Ampicillin Shanghai Bioengineering AB0064 Kanamycin Solebao K8020 tetracycline Shanghai Bioengineering A100422-0010 Trypsin Shanghai Bioengineering A003702-0100 10% AEBSF Shanghai Bioengineering C510022 TMB single component colorimetric solution Solebao PR1200 M13Bacteriophage Antibody (HRP), Mouse Mab Sino Biological 11973-MM05T-H HRP-labeled anti-his tag antibody (mouse anti-his-HRP) Sino Biological 105327-MM02T-H Goat anti-rabbit antibody conjugated with HRP (goat anti-rabbit) Sino Biological SSA004 Anti-his tag antibody Sino Biological 105327-MM02T Chloroauric acid Shanghai Test 10010711 Trisodium citrate dihydrate Shanghai Bioengineering A610035-0500 Anhydrous potassium carbonate Maclean P816304 sucrose Shanghai Bioengineering A610498-0500 Base Plate Hangzhou Fenghang Technology FH-DB-8025 Sartorius CN140 Hangzhou Fenghang Technology FH-NC-8003 Absorbent pad Hangzhou Fenghang Technology FH-AN3 Glass Fiber Hangzhou Fenghang Technology FH-8975 Plastic card shell Hangzhou Fenghang Technology FH-SLK-002Y
[0064] (3) Source of instruments and equipment
[0065] Table 2 Sources and models of instruments and equipment required for the experiment
[0066] Instrument Name Instrument Manufacturer Instrument Model Snow ice machine Xinzhi XB-50 Ultrasonic cell disruptor Xinzhi JY88-IIN Constant temperature metal bath Youning GA15 Decolorization shaker Chilin Bell TS-200 Rotating disk mixer Chilin Bell QB328 Multifunctional ELISA reader Bio Tek Synergy Cytation 5 Protein purification system Bio-Rad NGC Centrifuge Beckman X-30R Ultrapure water preparation system Merk Millipore Milli-Q Direct Gel imaging system Analytik Jena ChemoStudio Plus 515 Plate washer Bio Tek 50TS Vertical Pressure Steam Sterilizer Yamato SQ510 Electronic balance Ohaus PX223ZH Ultra-low temperature refrigerator Haier DW-86L486HC Protein electrophoresis system Bio-Rad Mini-Protean Medical Refrigerator Freezer Haier HYCD-282 Clean bench Haier HCB-1300V Liquid nitrogen tank Haier YDS-35-80 Constant temperature shaking incubator (shaker) smart city ZWY-211B Electric constant temperature incubator (referred to as incubator) smart city ZXDP-B2050 PCR instrument Thermo Fisher Mini Amp Film marking machine Hangzhou Fenghang HGS510 Programmable cutting machine Hangzhou Fenghang HGS201 Wide cutting machine Hangzhou Fenghang HG220S Flat shell pressing machine Hangzhou Fenghang HGS803 Film marking machine Hangzhou Fenghang HGS510
[0067] (4) Solutions and preparation methods required for the experiment
[0068] Table 3 Solutions and methods required for the experiment
[0069] Reagent name Preparation method LB liquid medium 1% (w / v) tryptone, 0.5% (w / v) yeast extract, 1% (w / v) NaCl, autoclave at 121°C for 20 min LB solid medium 1% (w / v) tryptone, 0.5% (w / v) yeast extract, 1% (w / v) NaCl, 1.5% (w / v) agar powder, autoclaved at 121°C for 20 min 10×SDS-PAGE electrophoresis buffer 250 mM Tris-HCl, 2.5 M glycine, 1% (w / v) SDS TBS 10 mM Tris-HCl, pH 8.0, 150 mM NaCl TBST 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween20 Blocking solution 5% skim milk powder dissolved in TBST Electroporation Buffer 25 mM Tris-HCl, 192 mM glycine, 20% methanol, freshly prepared and pre-cooled before use PBST Dilute 20× PBS buffer 20 times to 1× PBS and add 0.1% Tween20 Primary Antibody The primary antibody used in the Western blot experiment was a mouse monoclonal antibody, diluted 1:3000 in blocking solution. Secondary Antibodies The secondary antibody used in the Western blot experiment was goat anti-mouse antibody, diluted 1:5000 in blocking solution. 2×YT liquid medium <![CDATA[0.5 g of NaCl, 1.6 g of Tryptone, 1 g of Yeast Extract, dissolved in an appropriate amount of double deionized water (ddH 2 O, Double Distilled Water), after complete dissolution, make up the volume to 100 mL, autoclave at 121 °C for 20 min, and store at 4 °C for later use.]]> PEG / 2.5M NaCl (5×) <![CDATA[Weigh 100 g of PEG-8000 and 75 g of NaCl (2.5 M), dissolve them in 400 mL of ddH 2 O at room temperature, make up the volume to 500 mL, autoclave, stir to cool down, and store at 4°C.]]> 2×YT solid medium (Amp) <![CDATA[Dissolve 0.5 g of NaCl, 1.6 g of Tryptone, 1 g of Yeast Extract, and 1.5 g of Agarose B in an appropriate amount of ddH 2 O. After complete dissolution, make up the volume to 100 mL, autoclave at 121 °C for 20 min. Wait for the temperature of the medium to drop to about 50 °C, add Amp (100 μg / mL), pour the plates. After the medium solidifies, invert and store at 4 °C.]]> 2×YT solid medium (Tet) <![CDATA[0.5 g of NaCl, 1.6 g of Tryptone, 1 g of Yeast Extract, 1.5 g of Agarose B are dissolved in an appropriate amount of ddH 2 O. After complete dissolution, the volume is made up to 100 mL, and it is autoclaved at 121 °C for 20 min. When the temperature of the medium drops to about 50 °C, Tet (10 μg / mL) is added, and the plates are poured. After the medium solidifies, it is stored inverted at 4 °C.]]> Ampicillin (stock solution) Accurately weigh 2.5 g of ampicillin and place it in a 50 mL centrifuge tube. Add 40 mL of sterile water, mix thoroughly to dissolve and make up to 50 mL. Filter with a 0.22 μm filter membrane for sterilization, divide into portions (1 mL / tube), and store at -20°C. Kanamycin (stock solution) Accurately weigh 2.5 g of kanamycin and place it in a 50 mL centrifuge tube. Add 40 mL of sterile water, mix thoroughly to dissolve and make up to 50 mL. Filter with a 0.22 μm filter membrane for sterilization, divide into portions (1 mL / tube), and store at -20°C. Tetracycline (stock solution) Accurately weigh 2.5 g of tetracycline and place it in a 50 mL centrifuge tube. Add 40 mL of anhydrous ethanol and mix thoroughly to dissolve the mixture. Make up to 50 mL of the solution and filter it with a 0.22 μm filter membrane for sterilization. After aliquoting (1 mL / tube), store it at -20°C. CBS Add 3.03 g Na2CO3 and 6.0 g NaHCO3 into 1 L sterile water, dissolve thoroughly, and store at 4°C. 0.25 mg / mL Trypsin Accurately weigh 12.5 mg of Trypsin into a 50 mL centrifuge tube, add sterile water, mix thoroughly and dissolve to make up to 50 mL. <![CDATA[0.2 M K 2 CO 3 Aqueous solution]]> Accurately weigh 0.2764 g of anhydrous potassium carbonate powder and add purified water to make up to 10 g. 10% BSA solution Accurately weigh 1 g of bovine serum albumin powder and add purified water to make up to 10 g. Gold complex solution Accurately weigh 0.1 g bovine serum albumin powder and 0.2 g sucrose, pipette 250 μL pH8.0 Tris-HCL, 10 μL Tween20, and then add purified water to 10 g. Gold diluent Accurately weigh 0.2 g bovine serum albumin powder and 0.5 g sucrose, pipette 250 μL pH8.0 Tris-HCL, 10 μL Tween20, and then add purified water to 10 g.
[0070] Example 1
[0071] The expression and purification of pirA and pirB antigen proteins include the following steps.
[0072] The construction of S1, pirA, and pirB recombinant plasmids, the specific steps are as follows:
[0073] (1) Based on the gene sequences of pirA (GenBank: KM067908.1:17198-17533) and pirB (GenBank: KM067908.1:17546-18862) of the pathogenic factors of Vibrio parahaemolyticus published in NCBI, the pirA and pirB genes were synthesized respectively, and gene-specific primers were designed using Primer Premier 5.0 (Table 4, SEQ ID NO. 1-6).
[0074] Table 4 Primer sequences used for amplification and sequencing of pirA and pirB genes
[0075] Primers Sequence (5'-3') Sequence number pirA-F AGTAACAATATAAAACATGAAACTGACTATTC SEQ ID NO.1 pirA-R TTAGTGGTAATAGATTGTACAGAAACCAC SEQ ID NO.2 pirB-F ACTAACGAATACGTTGTAACAATGTCATC SEQ ID NO.3 pirB-R CTACTTTTCTGTACCAAATTCATCGG SEQ ID NO.4 T7 TAATACGACTCACTATAGGG SEQ ID NO.5 T7-Ter TGCTAGTTATTGCTCAGCGG SEQ ID NO.6
[0076] (2) The pirA and pirB genes were amplified by the first round of PCR reaction. The first round of PCR reaction system was: 1 μL of synthetic pirA and pirB gene template DNA, 2 μL each of pirA / BF / R (10 μM), 25 μL of 2 × Phanta MaxMaster Mix (high-fidelity DNA polymerase mixture), and ddH 2 O was diluted to a total volume of 50 μL, vortexed to mix, and the first round of PCR reaction was performed after a brief centrifugation. The first round of PCR reaction program was: pre-deformation at 98°C for 30 s, denaturation at 98°C for 10 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s. The denaturation to extension process was repeated for 30 cycles, followed by full extension at 72°C for 2 min and storage at 4°C. This was the first amplification product of pirA and pirB.
[0077] (3) After the first round of PCR reaction, the first amplification products of pirA and pirB were separated by 1.5% agarose gel electrophoresis, and the bands of about 336 bp and 1317 bp were cut out by UV gel excision instrument, respectively, and recovered by agarose DNA recovery kit. These are the target genes pirA and pirB. The specific electrophoresis results are shown in Figure 1 .
[0078] (4) The target genes pirA and pirB were subjected to enzyme ligation reaction with the vector respectively. The enzyme ligation reaction system was: 4 μL of target gene, 1 μL of pEASY®-Blunt E1 Expression Vector. After gently pipetting to mix, react at 25°C for 10 min. This is the first ligation product of pirA and pirB. Store at 4°C until use.
[0079] (5) Thaw the Trans-T1 competent cells (competent cells included in the pEASY®-Blunt E1 Expression Kit) on ice, and add the first ligation products of pirA and pirB to 50 μL of Trans-T1 competent cells, mix gently, and quickly place on ice for 30 min, heat shock in a 42°C metal bath for 30 s, and immediately place on ice for 2 min. Under a sterile environment, add the transformed bacterial solution to 250 μL of non-resistant LB liquid culture medium, shake and culture at 37°C, 220 rpm, for 1 h, which is the first transformation bacterial solution of pirA and pirB. Subsequently, take 200 μL of the first transformation bacterial solution of pirA and pirB and spread them on ampicillin (Amp, Amipicilline) resistant LB solid culture medium, and culture them upside down in an incubator at 37°C overnight, which is the first plate of pirA and pirB.
[0080] (6) Pick the monoclonal plaques from the first plate of pirA and pirB for expansion culture, which is the first monoclonal bacterial solution of pirA and pirB. Then take 1 μL of the first monoclonal bacterial solution of pirA and pirB for the second round of PCR reaction. The second round PCR reaction system is: 2 × Rapid Taq Master Mix 10 μL, first monoclonal bacterial solution 1 μL, T7 (SEQID NO.5) 1 μL, pirA / BR 1 μL, add ddH 2O was fixed to 20 μL. The second round of PCR reaction program was: pre-deformation at 95℃ for 10 min, denaturation at 95℃ for 15 s, annealing at 60℃ for 15 s, and extension at 72℃ for 5 s. The denaturation to extension process was repeated for 28 cycles, followed by full extension at 72℃ for 5 min. The second amplification products of pirA and pirB were stored at 4℃ for future use. The second amplification products of pirA and pirB were detected by 1.5% agarose gel electrophoresis. The fragment sizes were approximately 336 bp and 1317 bp, respectively. See the specific electrophoresis verification diagram for details. Figure 2 .
[0081] (7) Select the positive clones of the second amplification products of pirA and pirB and expand the culture. Place them on a shaker and culture them at 200 rpm and 37°C for about 6 hours. After extracting the plasmid using a plasmid extraction kit, take an appropriate amount of plasmid and send it to Biotechnology. Use T7 and T7 Ter (SEQID NO.6) universal primers for the first sequencing. The first sequencing results are compared and analyzed, and the similarity is 100%. Therefore, the recombinant protein plasmid vector is successfully constructed, namely the pirA plasmid and pirB plasmid. Mark them and store them in a -20°C refrigerator.
[0082] The specific steps for expression and purification of S2, pirA, and pirB antigen proteins are as follows:
[0083] (1) According to the first sequencing results, select the pirA plasmid and pirB plasmid with correct sequence alignment, and clone them into the pEASY®-Blunt E1 vector respectively. Except for the difference in transformation into BL21 (DE3) competent cells, the transformation method is the same as S1 (5). After the plating is completed, invert and culture in an incubator at 37°C overnight to form the second pirA and pirB plates. Pick a single colony from the second pirA and pirB plates and culture it in 16 mL of Amp-resistant LB liquid culture medium overnight to form the second monoclonal bacterial solution of pirA and pirB. After overnight culture, inoculate 16 mL of the second monoclonal bacterial solution of pirA and pirB into 1.6 L of Amp-resistant LB liquid culture medium at a ratio of 1:100 to form the first amplification bacterial solution of pirA and pirB. Place it in a shaker at 37°C and 220 rpm for about 4 h. When the OD of the first amplification bacterial solution reaches 0.04, the pirA and pirB second monoclonal bacterial solution is inoculated into 1.6 L of Amp-resistant LB liquid culture medium at a ratio of 1:100 to form the first amplification bacterial solution of pirA and pirB. 600 nm=0.6, add IPTG (isopropyl β-D-Thiogalactoside) with a final concentration of 1 mM, and induce at 37°C for 4 h to obtain the bacterial solution after the first induction of pirA and pirB. The bacterial liquid after the first induction of pirA and pirB was transferred to large centrifuge bottles respectively, and centrifuged at 4°C, 4700 rpm for 15 min. The supernatant was discarded and the bacterial pellet was retained as the first pellet of pirA and pirB. Then 30 mL of 1×PBS (phosphate buffered saline) was added to resuspend the first pellet of pirA and pirB to obtain the first resuspension of pirA and pirB. Then, an ultrasonic cell disruptor was used with 30% power, ultrasonication for 2 s, intermittent 4 s, and a total ultrasonication time of 60 min to obtain the second resuspension of pirA and pirB. The second resuspension of pirA and pirB was divided into 2 mL centrifuge tubes and centrifuged at 13000 rpm at 4°C for 30 min to collect the supernatant as the first supernatant of pirA and pirB.
[0084] (2) Take 2 mL of Ni-NTA (nickel NTA affinity chromatography medium, referred to as nickel column), balance the nickel column with 20 mL of ultrapure water and PBS respectively, filter the first supernatant of pirA and pirB through a 0.22 μm filter membrane respectively, and inject it into the nickel column to obtain the pirA and pirB loading fluid FT; wash the nickel column with 20 mL of 40 mM imidazole solution to remove impurities, which is pirA and pirB 40 mM imidazole wash impurities; elute the target protein with 20 mL of 200 mM imidazole solution, which is pirA and pirB 200 mM imidazole wash impurities (pirA, pirB proteins), then wash the nickel column with 10 mL of 1 M imidazole solution to remove the remaining impurities on the column, and finally rinse the column with 20 mL of ultrapure water. Store the nickel column in 20% ethanol and place it in a 4°C refrigerator.
[0085] (3) Take 40 μL of the first culture of pirA and pirB, the first culture after induction of pirA and pirB, the second resuspension of pirA and pirB, the first supernatant of pirA and pirB, the flow-through FT of pirA and pirB, the 40 mM imidazole-washed proteins of pirA and pirB, and the protein samples of pirA and pirB, and mix them with 10 μL of 5× loading buffer. Heat and denature them in a metal bath at 99°C for 10 min, centrifuge at 13,000 rpm for 10 min, and prepare the first PAGE gel (polyacrylamide gel electrophoresis) of pirA and pirB using a 12.5% Omni-Easy™ One-Step PAGE Gel Rapid Preparation Kit. The electrophoresis conditions are 200 V and 35 min. After the electrophoresis is completed, the PAGE gel is stained with SDS-PAGE rapid stain and decolorized with tap water. It was clearly observed that there were obvious bands of pirA protein at 13 kDa and pirB protein at 52 kDa. The protein was successfully expressed and the purity was good. The subsequent experiments can be continued. The specific pirA and pirB protein expression and purification diagrams are shown in Figure 3 , Figure 4 .
[0086] (4) The pirA protein and pirB protein were desalted by PD-10 column according to the instructions to remove imidazole and other salts, and concentrated by 10 kDa concentrator to obtain pirA antigen protein and pirB antigen protein. The concentration of pirA and pirB antigen protein was determined by BCA kit. The pirA antigen protein (diluted 10 times) and pirB antigen protein (diluted 100 times) were at OD 562 nm The absorbance values were 0.2 and 0.347, respectively. Combined with the fitting equation y=0.7615x+0.0806 in the BCA protein concentration determination standard curve, the pirA and pirB antigen protein concentrations were measured to be approximately 1.6 mg / mL and 35.0 mg / mL, respectively. After packaging, they were quickly frozen in liquid nitrogen and stored in a -80°C refrigerator. For specific BCA protein concentration determination standard curve, see Figure 5 .
[0087] Western blot verification of S3, pirA, and pirB antigen proteins
[0088] (1) SDS-PAGE electrophoresis, the method is the same as S2 (3), that is, the second PAGE gel. The specific SDS-PAGE electrophoresis results are shown in Figure 6 .
[0089] (2) After electrophoresis, take out the second PAGE gel and soak it in ddH 2O, cut a PVDF membrane (polyvinylidene fluoride) of the same size as the second PAGE gel and immerse it in methanol to activate it as the first PVDF membrane. Arrange it in the order of negative electrode to positive electrode: sponge pad-filter paper-PAGE gel-PVDF membrane-filter paper-sponge pad, remove bubbles with a roller, clamp it and put it into the transfer machine. Pour in the pre-cooled transfer solution, cover the transfer machine and bury it in ice, set the parameters to 250 mM, 1 h.
[0090] (3) Washing: After transfer, remove the first PVDF membrane and wash it three times with TBST (Tris Buffered Saline with Tween 20), each time for 5 min.
[0091] (4) Blocking: Add 5% skimmed milk powder solution and block at room temperature for 2 h.
[0092] (5) Incubation with primary antibody: Discard the blocking solution and add pre-diluted mouse monoclonal antibody as the primary antibody and incubate at room temperature for 1 h.
[0093] (6) Washing: Wash three times with TBST, turn over and wash three more times, 5 min each time.
[0094] (7) Incubation with secondary antibody: Add pre-diluted goat anti-mouse HRP antibody and incubate at room temperature for 1 h.
[0095] (8) Washing: Wash three times with TBST, turn over and wash three more times, 5 min each time.
[0096] (9) Add ECL colorimetric solution to the first PVDF membrane and place it in the dark for 2 min. The protein is indeed a His-tagged protein (the theoretical sizes of pirA antigen protein and pirB antigen protein are 13 kDa and 52 kDa, respectively). See the Western blot identification results of pirA antigen protein and pirB antigen protein for details. Figure 7 .
[0097] Example 2
[0098] The pirA and pirB antigen proteins obtained in Example 1 were used to screen pirA and pirB nanoantibodies using alpacas, including the following steps.
[0099] S1. Construction of camel-derived natural library. The specific steps are as follows:
[0100] The alpaca natural library used in this experiment was purchased from Shenzhen Kangti Life Science Technology Co., Ltd.
[0101] According to the experimental report provided by Kangti Life, the blood samples of the library were collected from 103 healthy alpacas. After total RNA extraction, reverse transcription, PCR amplification, vector and PCR product enzyme ligation, 20 electroporation transformations were performed to collect all bacterial liquid to construct a bacterial library. 48 single colonies were randomly selected from the bacterial library for colony PCR, and the positive clone rate reached 96%. After sequencing, the protein sequence was compared for diversity. The results showed that all the sequences sent for testing were independent sequences, and the diversity of the bacterial library reached 100%, which met the requirements. The bacterial library was rescued and purified using M13K07-assisted phage, and its titer was tested. The final library capacity was 2.3×10 9 pfu bacterial library and a titer of 1.2×10 12 pfu / mL of phage library.
[0102] S2. Amplification, purification and titer determination of auxiliary phage. The specific steps are as follows:
[0103] (1) Activation: Streak the SS320 E. coli glycerol culture stored in the laboratory on a 2×YT (tetracycline resistance) solid culture medium and incubate it upside down in an electric constant temperature incubator at 37°C overnight to make the third plate. Pick the monoclonal colony from the third plate and add it to 5 mL of tetracycline resistance (Tet, Tetracyclines) 2×YT liquid culture medium and shake the culture at 37°C overnight to make the third monoclonal bacterial liquid.
[0104] (2) Amplification: Transfer the third monoclonal bacterial solution to 100 mL 2×YT (tetracycline resistance) liquid culture medium and shake at 37°C and 220 rpm until the logarithmic phase. Add helper phage M13K07 according to the following formula:
[0105] ,
[0106] Note: To assist phage titer, =1.6×10 13 pfu / mL; OD 600 is the OD of the bacterial solution when the helper phage is added 600 nm Absorbance value.
[0107] After continuing to culture in a 37°C shaker for 30 min, kanamycin with a final concentration of 50 μg / mL and IPTG with a final concentration of 0.2 mM were added thereto under a sterile environment, and then cultured in a shaker at 30°C overnight to obtain the second induced bacterial solution.
[0108] (3) Purification: Centrifuge the second post-induction bacterial solution of pirA and pirB at 4°C and 4000 rpm for 10 min, retain the supernatant, and transfer the second supernatant of pirA and pirB to a new tube, add 1 / 4 volume of pre-cooled 20% PEG / NaCl to it, mix well, and place on ice for 30 min. Then centrifuge at 4°C and 4000 rpm for 20 min. Discard the supernatant and retain the precipitate, which is the second precipitate of pirA and pirB, and invert it on paper for 2 min. Then add 1 mL 1×PBS and repeatedly blow to suspend the second precipitate of pirA and pirB and transfer it to a new 1.5 mL tube, add a quarter volume of pre-cooled 20% PEG / NaCl again, mix well, and place on ice for 10 min. Centrifuge at 4°C and 12,000 rpm for 10 min, remove the supernatant and retain the precipitate, which is the third precipitate of pirA and pirB. Add 1 mL of 1×PBS and repeatedly blow to suspend the third precipitate of pirA and pirB. Centrifuge at 4°C and 12,000 rpm for 2 min. Carefully aspirate the supernatant and divide it into 1.5 mL tubes, 100 µL in each tube, which is the third supernatant of pirA and pirB. Store in a -80°C refrigerator for long-term use.
[0109] (4) Titer determination: Culture 5 mL of SS320 E. coli in advance until OD 600 nm Take 10 μL of the third supernatant of pirA and pirB prepared in (3) and dilute them in a 10-fold concentration gradient (10 μL in each tube + 90 μL sterile water) to 10 -12 , a total of 12 tubes, mix well for later use. Add 90 μL of SS320 logarithmic phase bacterial solution to each tube, pipette and mix well, incubate at 37°C for 30 min, then take 5 μL from each tube to kanamycin resistance (Kana, Kanamycin ) 2×YT solid plate, incubate at 37°C overnight, which is the fourth plate for pirA and pirB. Count the number of single colonies on the fourth plate of pirA and pirB at each dilution, and calculate the helper phage titer according to the following formula: Where N is the number of colonies at a certain dilution factor, and D is the dilution factor.
[0110] S3. Panning of anti-pirA and pirB phage libraries. The specific steps are as follows:
[0111] (1) First round of screening: First, pirA and pirB antigen proteins were coated. 50 µg of pirA and pirB antigen proteins were coated on immunotubes A and B respectively. The coating solution was 2 mL CBS (Carbonate Buffer solution). After being placed in a 4°C low-temperature incubator and rotated slowly overnight, the CBS-free coating solution was discarded and the immunotubes were rinsed three times with 1× PBS for 5 min each time. Subsequently, 2 mL of 3% BSA was added as blocking solution and the blocking was performed at room temperature for 2 h. The 3% BSA blocking solution was discarded and the immunotubes were rinsed three times with 1× PBS for 5 min each time. After discarding the rinsing solution, 2 mL of 1× PBS was added, and then the camel-derived natural phage library (provided by Shenzhen Kangti Life Science Technology Co., Ltd., with a titer of 1.2×10 13 pfu / mL), incubate with rotation at room temperature for 1 h, and discard the liquid in the immunotube. Add 2 mL PBST to wash the tube 20 times, rotating slowly for 5 min each time. Discard the liquid in the immunotube. Add 1 mL 0.25 mg / mL trypsin solution, and elute the phages with slow rotation at room temperature for 30 min. Then add 10 µL 10% AEBSF protease inhibitor to terminate the elution, and transfer the trypsin eluate in the immunotube to a new 1.5 mL tube, which is the first round of panning eluate for pirA and pirB.
[0112] (2) The first round of titer detection: the method is the same as S2 (4).
[0113] (3) First round of eluate expansion: Culture two tubes of 5 mL SS320 bacterial solution to the logarithmic phase in advance, and make the OD 600 nm It is about 0.5-0.55, set aside. Take 500 μL of the first round of panning elution of pirA and pirB (the remaining elution was stored at 4°C and added to the newly cultured 5 mL SS320 bacterial solution. Place it in a shaker at 37°C and infect at 250 rpm for 30 min. Evenly spread the entire 5.5 mL of bacterial solution after infection on three 130×130 mm 2×YT square culture media (containing 2% glucose, 2% agarose and 100 μg / mL Amp), 3 plates each for pirA and pirB, a total of 6 plates, and cultured upright at 37°C overnight, which is the fifth plate of pirA and pirB. Add 2 mL of Tet-resistant 2×YT liquid culture medium to the surface of the fifth plate, scrape all the colonies on the plate with a cell scraper and collect the mixed bacterial solution into a 15 mL centrifuge tube, which is the first mixed bacterial solution of pirA and pirB, 6 mL in each tube, and measure the OD of the bacterial solution at the same time. 600nmThen add glycerol with a final concentration of 20% to the first mixed bacterial solution of pirA and pirB, and store it in aliquots at -80°C, which is the bacterial library of the first round of eluate of pirA and pirB. 600 nm Substitute the value into the following formula: V (μL) = 10 / OD 600 ×1000, calculate the volume of the first bacterial culture of pirA and pirB, and transfer it to 100 mL Amp and Tet resistance 2×YT liquid medium, which is the second culture of pirA and pirB. At this time, the initial OD of the second culture of pirA and pirB is 600 nm = 0.1. 37℃, 220 rpm shaking to logarithmic phase and then measure OD 600 nm The volume of helper phage added is based on the following formula (T_(helper-phage) is the titer of the helper phage used):
[0114] ,
[0115] After being placed in a 37°C shaker for further culturing for 30 min, kanamycin with a final concentration of 50 μg / mL and IPTG with a final concentration of 0.2 mM were added thereto under a sterile environment, and then placed in a shaker for culturing at 30°C overnight to obtain the bacterial solution after the third induction of pirA and pirB.
[0116] (4) Purification of the first-round phage sub-library: The process is the same as S2 (4). After purification, the pirA and pirB first-round phage sub-libraries are obtained and used as the input phage library for the second round of screening.
[0117] (5) Second round of panning: The method is the same as S3 (1), except that the phage library added is the phage sub-library obtained in the first round of screening (about 10 12 pfu), and screened to obtain the second round screening eluate of pirA and pirB. The titer detection, amplification and purification steps of the phage eluate were the same as S3 (2, 3). Finally, the pirA and pirB second round phage sublibraries were purified and used as the input phage library for the third round of screening.
[0118] (6) The third round of panning: The method is the same as S3 (1), and the phage library added is the second round phage sub-library of pirA and pirB (about 10 12 pfu), and finally the eluate of the third round of screening of pirA and pirB was obtained.
[0119] From the three rounds of screening data of pirA and pirB, the recovery rate and elution volume of the first two rounds increased round by round, indicating that the phages of nano-antibodies against these two antigens were effectively enriched (enrichment was 70 and 48, respectively); after the third round of panning, the enrichment of pirA and pirB did not increase significantly (the enrichment of pirB was even less than 1), so the phages enriched in the second round were mainly the target phages, and the specific results are shown in Tables 5 and 6. The results show that this method can effectively enrich nano-antibodies that specifically bind to pirA and pirB. Then phage-ELISA (phage display technology) was used to further detect its affinity.
[0120] Table 5 Results of three rounds of panning of anti-pirA nanobodies in natural phage library
[0121]
[0122] Recovery rate = elution amount ÷ input amount,
[0123] Enrichment = recovery rate of the next round ÷ recovery rate of the previous round.
[0124] Table 6 Results of three rounds of panning of anti-pirB nanobodies in natural phage library
[0125]
[0126] S4. Identification and analysis using phage-ELISA. The specific steps are as follows:
[0127] (1) Preparation of phage supernatant
[0128] Prepare 5 mL culture of SS320 E. coli to OD 600 nm The value is about 0.5, which is reserved. Take 10 μL of the eluate from the third round of screening of pirA and pirB and dilute them in a 10-fold concentration gradient (10 μL + 90 μL sterile water in each tube) to 10 -12 , a total of 12 tubes, mix well for later use. Add 90 μL of SS320 logarithmic phase bacterial solution to each tube, pipette to mix well, and culture at 37°C for 30 min to prepare the third culture solution for pirA and pirB. Take 5 μL from each tube of the third culture solution for pirA and pirB to 12 Amp-resistant 2×YT solid culture plates in turn, and evenly spread the bacterial solution, invert and culture at 37°C overnight to prepare the sixth plate for pirA and pirB. Take a sterile 96-well cell culture plate, add 200 μL of Amp- and Tet-resistant 2×YT liquid culture medium to each well, then use a sterile pipette tip to randomly pick 96 monoclonal clones from the sixth plate and add them to each well, and place them in a 37°C incubator for overnight culture to prepare the first cell culture plate for pirA and pirB.
[0129] Take 2 μL of the bacterial solution in each well of the first cell culture plate of pirA and pirB (the remaining bacterial solution is stored at 4℃) and transfer it to a new 96-well cell culture plate, place it in a 37℃ incubator and culture it for 3 hours to form the second cell culture plate of pirA and pirB. Then calculate the volume of helper phage added to each well according to the following formula (T_(helper-phage) is the titer of the helper phage used):
[0130] ,
[0131] After being placed in a 37°C incubator for 30 minutes, kanamycin with a final concentration of 50 μg / mL and IPTG with a final concentration of 0.2 mM were added under a sterile environment, and then placed in a shaker for overnight culture at 30°C to obtain the fourth induced bacterial solution of pirA and pirB. Subsequently, the second cell culture plate of pirA and pirB was centrifuged at 4°C for 10 minutes at 4000 rpm to obtain the first phage supernatant of pirA and pirB.
[0132] (2) Phage-ELISA identification
[0133] 96-well ELISA plates were coated with pirA and pirB antigen proteins, respectively. The coating solution was CBS (antigen concentration was 1 ng / μL, and the coating volume was 100 μL / well). Two 96-well ELISA plates with BSA (BSA concentration was 1 ng / μL, and the coating volume was 100 μL / well) were set as control groups. They were all placed in a 4°C low-temperature incubator for overnight coating. The next day, the coating solution was discarded, and each well was rinsed three times with 200 μL PBS, and each time was allowed to stand for 5 min. 200 μL of 3% BSA was added as blocking solution, and the plates were blocked at room temperature for 1 hour. The blocking solution was discarded, and 200 μL of 0.1% PBST was added to each well, the blocking solution was washed off, and the plates were washed three times at room temperature, and each time was allowed to stand for 10 min.
[0134] Then, the phage supernatant was incubated, and 120 µL of 3% BSA was added to each well of the 96-well ELISA plate, followed by 80 µL of the first phage supernatant of pirA and pirB as the primary antibody. The plates were incubated at room temperature for 2 h, the primary antibody was discarded, and each well was rinsed three times with 200 µL of PBS, each for 10 min. Then, M13 mouse anti-phage monoclonal antibody (HRP labeled) was added as the secondary antibody, diluted 1:40000 in 3% BSA, 100 µL was added to each well, and the plates were incubated for 1 h at room temperature. The secondary antibody was discarded, and 200 µL of PBST was added to each well for washing, and the plates were washed three times at room temperature, each for 10 min. Then, color development was performed: TMB single-component color development solution was used to develop each well, 100 µL was added to each well, and color development was performed in the dark for about 3 min, and then 100 µL of HCl (1 M) was used to stop color development. The OD was read using an ELISA reader. 450 nm Numeric value.
[0135] When processing the color development results, compare the OD values of the pirA and pirB antigen protein incubation wells with the corresponding BSA coated control wells. 450 nm The ratios of the values are ranked from large to small. The specific phage-ELISA identification results are shown in Figure 8 , 9 The monoclonal bacterial solutions with the top 10 ratios (≥1.65) were selected for pirA, and the monoclonal bacterial solutions with the top 30 ratios (≥6.33) were selected for pirB. A total of 40 monoclonal bacterial solutions were sent to Shanghai Biotechnology Co., Ltd. for sequencing. The primer required for sequencing was pADL-F (SEQ ID NO. 7): TGTGAGCGGATAACAATTTCAC. The sequencing result was the result of the second sequencing.
[0136] Example 3
[0137] The expression and identification of the VHH nanoantibodies against pirA and pirB antigen proteins obtained in Example 2 include the following steps.
[0138] S1. Construction of prokaryotic expression vector. The specific steps are as follows:
[0139] Sequence alignment analysis was performed based on the second sequencing results, and finally 13 VHH antibody amino acid sequences with different CDR3 regions were screened (including 3 pirA nanobodies: VHH-A1~A3 nanobody amino acid sequences as shown in SEQ ID NO.8~10; 10 pirB antibody nanosequences: VHH-B1~B10 nanobody amino acid sequences as shown in SEQ ID NO.11~20). The sequence alignment results are shown in Fig.10The 13 VHH antibody sequences were codon optimized, fully synthesized, and recombinant plasmids were constructed and cloned into the pET-28a prokaryotic expression vector.
[0140] S2. Transform the pET-28a-VHH recombinant plasmid into BL21 (DE3) competent cells. The specific steps are as follows:
[0141] Take 1 µL of pET-28a-VHH recombinant plasmid and add it to 50 µL of BL21 (DE3) competent cells, and place it on ice for 30 minutes. Then heat shock at 42℃ for 90 seconds, and immediately place it on ice for 5 minutes. In a sterile environment, add 900 µL of LB medium without resistance, and shake and culture it at 37℃ and 220 rpm for 45 minutes, which is the second transformation bacterial solution of pirA and pirB. Then take 100 µL of pirA and pirB second transformation bacterial solution and spread it on Kana resistance LB solid medium, and culture it upside down at 37℃ overnight, which is the seventh plate. The next day, pick a single colony from the seventh plate to 5 mL of Kana resistance LB liquid medium, shake and culture it at 37℃ and 220 rpm until the logarithmic phase, add glycerol and bacterial solution to the cryovial, and store it at -80℃, which is the BL21 (DE3) glycerol bacteria of pET-28a-VHH.
[0142] S3, bacterial culture and induced expression, the specific steps are as follows:
[0143] (1) Inoculate the BL21 (DE3) glycerol culture medium containing pET-28a-VHH into 10 mL of LB liquid culture medium with Kana resistance at a ratio of 1:100 and culture overnight at 37°C and 220 rpm to activate the bacteria. This is the fourth culture medium for pirA and pirB.
[0144] (2) Take 1 mL of the fourth culture of pirA and pirB as the uninduced sample. Transfer the rest to 800 mL of LB liquid medium with Kana resistance at a dilution of 1:1000 and shake at 37°C and 220 rpm until the OD reaches 0. 600 nm =0.6-0.8Add IPTG with a final concentration of 1 M and induce at 28°C, 220 rpm for 6 h to obtain the bacterial solution after the fifth induction of pirA and pirB.
[0145] (3) Take 1 mL of the fifth induction bacterial solution of pirA and pirB as SDS-PAGE electrophoresis samples, and put the remaining bacterial solution into large centrifuge bottles and centrifuge at 4700 rpm for 30 min at 4°C. Discard the supernatant and collect the bacteria. Resuspend each 800 mL of bacterial cell pair in 30 mL PBS in a 50 mL centrifuge tube and store at 4°C to prepare the third resuspension of pirA and pirB.
[0146] S4. Protein purification of VHH nanobodies (pirA nanobodies, pirB nanobodies). The specific steps are as follows:
[0147] (1) Ultrasonic disruption: Place the third resuspension of pirA and pirB on ice and ultrasonically disrupt for 30 min at 30% power, on for 2 s, off for 4 s until the solution is clear. Centrifuge the third resuspension at 4°C, 12,000 rpm for 30 min, and keep the supernatant as the fourth supernatant of pirA and pirB for subsequent nickel column.
[0148] (2) Equilibrate the nickel column: Take 2 mL of Ni-NTA and equilibrate it with 20 mL of water and PBS in sequence;
[0149] (3) Loading: Filter the fourth supernatant of pirA and pirB through a 0.22 μm filter membrane and slowly inject it into the nickel column;
[0150] (4) Washing: Add 20 mL of 20 mM and 40 mM imidazole washing solutions to wash out the impurities;
[0151] (5) Elution: Add 20 mL of elution buffer containing 200 mM imidazole to elute the target protein, and collect all the collected fluid, which is the VHH-A1~A1 nanobody protein and VHH-B1~B10 nanobody protein (theoretical size is 14.4 kDa~16.3 kDa);
[0152] (6) Washing: Add 10 mL of PBS containing 1 M imidazole to wash away the uneluted proteins, then add 10 mL of ultrapure water for washing. Add 20% ethanol aqueous solution and cover the column. Store in a refrigerator at 4°C.
[0153] (7) Electrophoresis: Use the Omni-Easy™ One-Step PAGE Gel Rapid Preparation Kit to prepare a 15% third PAGE gel. Take 40 μL of the target protein sample eluted in (5) in S4 above, add 5× loading buffer to prepare the sample, denature at 99°C for 10 min, centrifuge at 13,000 rpm for 10 min, take 10 μL of the supernatant after sample preparation and add it to the sample well. Set the electrophoresis conditions to 200 V and 40 min, and perform SDS-PAGE detection. The SDS-PAGE identification results are shown in Figure 2. Fig.11 ;
[0154] (8) Desalting and concentration: The VHH-A1~A1 nanobody protein and VHH-B1~B10 nanobody protein samples were passed through a PD-10 desalting column to remove salts such as imidazole, and the concentration of the VHH nanobody protein was determined using a BCA kit. 562 nm The absorbance value was combined with the fitting equation y=1.1733x+0.1726 in the BCA protein concentration determination standard curve. The final VHH-A1~A2 nanoantibody protein concentrations were 0.33 mg / mL and 0.17 mg / mL, respectively; the VHH-B1~B10 nanoantibody protein concentrations were approximately 0.45 mg / mL, 0.18 mg / mL, 0.36 mg / mL, 1.25 mg / mL, 0.56 mg / mL, 0.49 mg / mL, 0.60 mg / mL, 0.25 mg / mL, 0.30 mg / mL, and 0.19 mg / mL, respectively. After aliquoting, they were quickly frozen in liquid nitrogen and stored in a -80°C refrigerator. See the specific BCA protein concentration determination standard curve for details. Fig.12 .
[0155] S5. Western blot identification of VHH nanobody protein. The specific steps are as follows:
[0156] (1) SDS-PAGE electrophoresis: Use the Omni-Easy™ One-Step PAGE Gel Rapid Preparation Kit to prepare a 15% fourth PAGE gel. Take 40 μL of the VHH nanobody protein and add 10 μL of 5× loading buffer. Place it in a 99°C metal bath for 10 min and centrifuge it at 13,000 rpm for 10 min. The sample volume is 10 μL and the parameters are set to 200 V for 40 min.
[0157] (2) Electrophoresis: After electrophoresis, take out the fourth PAGE gel and soak it in ddH 2 O, immerse the PVDF membrane of the same size as the gel in methanol to activate it, for the second PVDF membrane, place it in order, remove bubbles with a roller, clamp it and put it into the transfer apparatus. Pour the pre-cooled transfer solution, cover the transfer apparatus and bury it in ice, set the parameters to 200 mM, 50 min.
[0158] (3) Washing: After transfer, remove the second PVDF membrane and wash it three times with TBST, each time for 5 min.
[0159] (4) Blocking: Add 5% skimmed milk powder solution and block at room temperature for 2 h.
[0160] (5) Incubation with primary antibody: Discard the blocking solution and add pre-diluted mouse monoclonal antibody as the primary antibody and incubate at room temperature for 1 hour.
[0161] (6) Washing: Wash three times with TBST, turn over and wash three more times, 5 min each time.
[0162] (7) Incubation with secondary antibody: Add pre-diluted goat anti-mouse HRP antibody) and incubate at room temperature for 1 h.
[0163] (8) Washing: Wash three times with TBST, turn over and wash three more times, 5 min each time.
[0164] (9) Add ECL colorimetric solution to the membrane and place it in the dark for 2 min. The protein specificity is good and there are no extra bands. The specific Western blot identification of VHH nanobody protein after purification is shown in Fig.13 .
[0165] S6. ELISA verifies the binding ability of VHH nanoantibodies to pirA and pirB antigen proteins. The specific steps are as follows:
[0166] (1) Antigen coating: Dilute pirA and pirB antigen proteins to 1 μg / mL with CBS coating solution, add 100 μL per well, and coat overnight at 4°C.
[0167] (2) Washing the plate: Pour out the liquid in the plate and pat dry on absorbent paper (be careful to avoid leaving fingerprints under the ELISA plate when patting dry to affect subsequent readings), and wash with PBST solution three times, 200 μL per well, 5 min each time.
[0168] (3) Blocking: 1% BSA solution (prepared in PBS), 100 μL per well, block at room temperature for 2 h.
[0169] (4) Washing the plate: Pour off the blocking solution and wash the plate three times with PBST solution, 200 μL per well, 5 min each time.
[0170] (5) Primary antibody: Each VHH nanobody and positive control were set up with different concentration gradients and 3 groups in parallel. VHH was incubated at about 10 -3 -10 3 Multiple concentration gradients were set between 10 ng / μL. The positive control was a custom-made rabbit polyclonal antibody corresponding to the pirA and pirB antigens. -5 -10 2 Multiple concentration gradients were set between ng / μL, and the negative control was PBS solution. 100 μL was added to each well and incubated for 1 h.
[0171] (6) Washing the plate: Discard the liquid in the plate and wash 10 times with 200 μL PBST.
[0172] (7) Secondary antibody: Add diluted enzyme-labeled antibody (mouse anti-his-HRP) to the corresponding wells of VHH nanoantibodies, the secondary antibody for the positive control is goat anti-rabbit antibody, and the negative control is PBS solution. Add 100 μL to each well. Incubate for 1 h.
[0173] (8) Washing the plate: Discard the liquid in the plate and wash 10 times with 200 μL PBST.
[0174] (9) Color development: Add 100 μL of TMB color development solution to each well and then place in the dark for about 5 min.
[0175] (10) Termination: After color development, add 50 μL 2M H 2 SO 4 Stop color development.
[0176] (11) Reading: OD on the microplate reader 450 nm Read the ELISA plate value.
[0177] Among them, the half effective concentration (EC 50 , median effect concentration) = 1.84 ng / μL, EC of Anti-pirA-pAb 50 =0.037 ng / μL, EC of VHH-B1 50 =0.94 ng / μL, EC of VHH-B2 50 =1.34 ng / μL, EC of VHH-B3 50 =24.29 ng / μL, EC of VHH-B4 50 =68.16 ng / μL, EC of VHH-B5 50 =5.05 ng / μL, EC of VHH-B6 50 =7.41 ng / μL, EC of VHH-B7 50 =1.66 ng / μL, EC of VHH-B8 50 =6.60 ng / μL, EC of VHH-B9 50 =4.84 ng / μL, EC of VHH-B10 50 =16.53 ng / μL, EC of Anti-pirB-pAb 50 =0.015 ng / μL. Except for VHH-A2, which had a general affinity effect, the half-effective concentration EC of each nanobody 50 =0.94~68.16 ng / μL, with good affinity to the corresponding antigen, and different concentrations of nanoantibodies have a good gradient effect. For specific VHH nanoantibody ELISA affinity verification diagram, see Fig.14a , Fig.14b , Fig.15a , Fig.15b , Fig.15c , Fig.15d , Fig.15e , Fig.15f , Figure 15g , Fig.15h , Fig.15i , Fig.15j , Figure 15k .
[0178] Example 4
[0179] The VHH nanobody obtained in Example 3 was initially applied to the colloidal gold chromatography test strip. The specific steps are as follows:
[0180] (1) Preparation of colloidal gold (20,000th of 30 nm colloidal gold)
[0181] Prepare a clean 250 mL conical flask, put in a B-type stirring rotor, and then put it on an electronic balance to peel. Add 189 g of pure water to the conical flask, and then use a pipette to add 2 g of 2% chloroauric acid solution. Transfer the flask to the heating stirrer, start heating, and adjust the speed so that the bottom edge of the stirring vortex is 0.5-1 cm away from the stirring rotor. Mark the speed and then turn off the stirring function. When many large bubbles attached to the stirring rotor in the flask slowly begin to rise (the temperature is about 95°C), turn off the heating function, turn on the stirring function, and quickly add 9 mL of 1% trisodium citrate aqueous solution. After the solution changes color to purple-red and reacts for 5 minutes, remove the flask and cool it to room temperature before use. It can be stored in a 4°C refrigerator for a long time.
[0182] (2) Labeling colloidal gold
[0183] Take 1 mL of colloidal gold solution in a 1.5 mL centrifuge tube, add 10 μL of 0.2 M potassium carbonate aqueous solution, and gently shake to adjust the pH value of colloidal gold. Then add 20 μg of VHH nanobody protein solution and mix at room temperature for 5 min to label the antibody. During the labeling process, the pirA nanobody binds to colloidal gold relatively smoothly, so VHH-A1, VHH-A2 nanobodies and rabbit polyclonal antibodies were used for subsequent experiments. The specific pirA nanobody binding to colloidal gold is shown in the figure. Fig.16 However, pirB nanoantibodies showed different degrees of dead gold after adding colloidal gold, that is, colloidal gold did not dissolve after adding gold diluent and the color became lighter. Therefore, VHH-B1, VHH-B2, VHH-B3, VHH-B6, VH-B8 nanoantibodies and rabbit polyclonal antibodies against pirB were selected for subsequent experiments. The specific binding of VHH nanoantibodies to colloidal gold is shown in Fig.17Then, add 30 μL of 10% BSA solution to the colloidal gold solution labeled with antibodies, and mix by inversion at room temperature for 5 min to block the colloidal gold.
[0184] Subsequently, the blocked colloidal gold solution was placed in a centrifuge and centrifuged at 8000 rpm for 6 min. The supernatant of the colloidal gold solution was carefully pipetted into a new centrifuge tube and centrifuged at 10000 rpm for 10 min. The supernatant was discarded. The precipitate obtained by centrifuging the blocked colloidal gold solution twice was re-dissolved in 50 μL of gold rehydration solution, and finally 100 μL of colloidal gold concentrate labeled with VHH antibody was obtained.
[0185] (3) Gold laying and drying
[0186] Cut the glass fiber into 0.5 cm wide strips and place them on the pad. Then dilute the concentrated gold solution in proportion (add about 300 μL of gold dilution solution to every 100 μL of concentrated solution) and slowly drip it onto the glass fiber. Then use a pipette to press evenly to spread the colloidal gold solution evenly on the glass fiber. Put it in an oven and adjust the temperature to 45°C for drying.
[0187] (4) Assembly and identification of test strips
[0188] Use a film stripper to strip two different antibodies at 1 μL / cm on the NC membrane as T line (test line) and C line (quality control line), and dry at 45°C. Then assemble the sample pad, NC membrane, absorbent paper, and gold label pad on the PVC base plate, overlap each two pads by about 0.2 cm, and then cut them into 4 mm wide test strips with a strip cutter. See the specific test strip structure diagram. Fig.18 Then, pirA antigen protein and pirB antigen protein with different concentration gradients were added to the sample pad for detection.
[0189] Comparative Example 1
[0190] The difference between this comparative example and Example 4 is that the antigen protein to be detected is different.
[0191] Among them, the antigen proteins used in Comparative Example 1 are MBP (tag protein), GST (tag protein), SWP1 (shrimp hepatocellular carcinoma virus isolation protein) and VP28 (white spot syndrome virus virulence protein), all of which are proteins that have been expressed, purified and preserved in the laboratory. The antigen protein used in Example 3 is pirA antigen protein or pirB antigen protein.
[0192] To further illustrate the advantages of the present invention, the antigen proteins used in Comparative Example 1 and Example 4 were subjected to the following test examples 1-6.
[0193] Test Example 1 pirA antigen protein detection
[0194] The pirA antigen protein in Example 1 was used to detect the colloidal gold test strip combination of Comparative Example 1 and Example 4. The combination of C line, T line and gold-labeled antibody in the colloidal gold test strip of the specific VHH nanobody is shown in Table 7.
[0195] Table 7 Combination of C line, T line and gold-labeled antibody in colloidal gold test strips for pirA antigen
[0196] Serial number C-line antibodies T-line antibody Gold labeled antibody 1 Anti-his tag antibody VHH-A2 VHH-A1 2 Anti-his tag antibody Rabbit polyclonal antibody VHH-A1 3 Anti-his tag antibody Rabbit polyclonal antibody VHH-A2 <![CDATA[ 4 ]]> <![CDATA[ Anti-his tag antibody ]]> <![CDATA[ VHH-A1 ]]> <![CDATA[ VHH-A2 ]]> 5 Goat anti-rabbit VHH-A1 Rabbit polyclonal antibody 6 Goat anti-rabbit VHH-A2 Rabbit polyclonal antibody
[0197] The pirA antigen protein prepared in Example 1 with a concentration of 1.0 mg / mL was used as the stock solution, and 100 μL of the pirA antigen protein was added dropwise to the colloidal gold test strips assembled in Comparative Example 1 and Example 4, respectively, and the color development result was observed after 5-10 min.
[0198] Test case 1 results are as follows Fig.19 As shown in the figure, only the T line No. 4 in the pirA colloidal gold test strip has a color development result, corresponding to the gold-labeled antibody being VHH-A2, the T line antibody being VHH-A1, and the C line antibody being an anti-his tag antibody. It can be seen that this antibody combination method can detect the pirA antigen protein.
[0199] Test Example 2: pirA antigen protein sensitivity test
[0200] The colloidal gold test strip No. 4 with color development in Test Example 1 was selected, that is, the gold-labeled antibody was VHH-A2, the T-line antibody was VHH-A1, and the C-line antibody was an anti-his tag antibody, to prepare a colloidal gold test strip for detecting pirA antigen protein. 100 μL of pirA antigen protein samples with concentrations of 1 mg / mL, 0.5 mg / mL, 0.25 mg / mL, 125 μg / mL, and 62.5 μg / mL were added to the test strips No. 1-5, respectively, and 100 μL of PBS was added to the test strip No. 6 as a blank control. The specific colloidal gold test strip C line, T line, gold-labeled antibody combination and antigen concentration are shown in Table 8. The line development was observed after about 5-10 minutes.
[0201] Test case 2 results are as follows Fig. 20 As shown, the color of the T line becomes lighter as the concentration of pirA antigen protein decreases, and the sensitivity is 125 μg / mL.
[0202] Table 8 The combination of C line, T line, gold-labeled antibody and antigen concentration in the sensitivity test of pirA antigen colloidal gold test strip
[0203] Serial number C-line antibodies T-line antibody Gold labeled antibody Sample concentration 1 Anti-his tag antibody VHH-A1 VHH-A2 1mg / mL 2 Anti-his tag antibody VHH-A1 VHH-A2 0.5mg / mL 3 Anti-his tag antibody VHH-A1 VHH-A2 0.25mg / mL 4 Anti-his tag antibody VHH-A1 VHH-A2 125 μg / mL 5 Anti-his tag antibody VHH-A1 VHH-A2 62.5 μg / mL 6 Anti-his tag antibody VHH-A1 VHH-A2 0
[0204] Test Example 3: Specific detection of pirA antigen protein
[0205] Select the No. 4 colloidal gold test strip combination with color development in Test Example 1, that is, the gold-labeled antibody is VHH-A2, the T-line antibody is VHH-A1, and the C-line antibody is an anti-his tag antibody, to prepare a colloidal gold test strip for detecting pirA antigen protein. Add 100 μL of 5 pathogenic proteins with a concentration of 1 mg / mL to the No. 1-5 test strips respectively: pirA, MBP, GST, SWP1, VP28. Observe the line development after about 5-10 minutes.
[0206] Test case 3 results are as follows Fig.21 It was shown that except for the test strip with pirA antigen protein added, which had an obvious T line, the other test strips had no T line, proving that pirA colloidal gold test strip No. 4 in Test Example 1 could specifically identify pirA antigen protein.
[0207] Test Example 4
[0208] Referring to Test Example 3, 100 μL of 1 mg / mL pathogenic protein was tested from a shrimp farming water sample enriched with the gold-labeled antibody VHH-A2, the T-line antibody VHH-A1, and the C-line antibody anti-his tag antibody. Fig.21 The basically identical pirA antigen colloidal gold test strip specificity test result graph indicates that the shrimp farming water sample contains Vibrio parahaemolyticus.
[0209] Test Example 5
[0210] Referring to Test Example 3, 100 μL of 1 mg / mL pathogenic protein solution enriched with shrimp aquaculture feed was tested by using a colloidal gold test strip prepared with a gold-labeled antibody of VHH-A2, a T-line antibody of VHH-A1, and a C-line antibody of anti-his tag antibody. Fig.21 The basically identical pirA antigen colloidal gold test strip specificity test result graph indicates that the shrimp farming feed solution contains Vibrio parahaemolyticus.
[0211] Test Example 6 pirB antigen protein detection
[0212] The pirB antigen protein in Example 1 was used to detect the colloidal gold test strip combinations of Comparative Example 2 and Example 4. The specific combinations of C line, T line and gold-labeled antibody in the colloidal gold test strip of VHH nanoantibodies are shown in Table 9.
[0213] Table 9 Combination of C line, T line and gold-labeled antibody in colloidal gold test strips for pirB antigen
[0214] Serial number C-line antibodies T-line antibody Gold labeled antibody 1 Anti-his tag antibody VHH-B1 VHH-B2 <![CDATA[ 2 ]]> <![CDATA[ Anti-his tag antibody ]]> VHH-B1 <![CDATA[ VHH-B3 ]]> 3 Anti-his tag antibody VHH-B1 VHH-B6 4 Anti-his tag antibody VHH-B1 VHH-B8 <![CDATA[ 5 ]]> <![CDATA[ Goat anti-rabbit ]]> VHH-B1 <![CDATA[ Rabbit polyclonal antibody <!-- 19 -->]]> 6 Anti-his tag antibody VHH-B2 VHH-B1 7 Anti-his tag antibody VHH-B2 VHH-B8 <![CDATA[ 8 ]]> <![CDATA[ Goat anti-rabbit ]]> VHH-B2 <![CDATA[ Rabbit polyclonal antibody ]]> 9 Anti-his tag antibody Rabbit polyclonal antibody VHH-B1 10 Anti-his tag antibody Rabbit polyclonal antibody VHH-B2 11 Anti-his tag antibody Rabbit polyclonal antibody VHH-B3 12 Anti-his tag antibody Rabbit polyclonal antibody VHH-B6 13 Anti-his tag antibody Rabbit polyclonal antibody VHH-B8
[0215] The pirB antigen protein prepared in Example 1 with a concentration of 1.0 mg / mL was used as the stock solution, and 100 μL of the pirB antigen protein was added dropwise to the colloidal gold test strips assembled in Comparative Example 2 and Example 3, respectively, and the color development result was observed after 5-10 min.
[0216] Test case 6 results are as follows Fig. 22 As shown, only the T lines of No. 2, No. 5, No. 8 and No. 11 of the pirB colloidal gold test strips have color development results, corresponding to the gold-labeled antibody of No. 2 colloidal gold test strip is VHH-B3, the T line antibody is VHH-B1, and the C line antibody is anti-his tag antibody; the gold-labeled antibody of No. 5 colloidal gold test strip is rabbit polyclonal antibody, the T line antibody is VHH-B1, and the C line antibody is goat anti-rabbit; the gold-labeled antibody of No. 8 colloidal gold test strip is rabbit polyclonal antibody, the T line antibody is VHH-B2, and the C line antibody is goat anti-rabbit; the gold-labeled antibody of No. 11 colloidal gold test strip is VHH-B3, the T line antibody is rabbit polyclonal antibody, and the C line antibody is anti-his tag antibody. It can be seen that the above four antibody combinations can detect pirB antigen protein.
[0217] Test Example 7 pirB antigen protein sensitivity detection
[0218] Select the colloidal gold test strip combination No. 8 with color development in Test Example 6, that is, the gold-labeled antibody is rabbit polyclonal antibody, the T-line antibody is VHH-B2, and the C-line antibody is goat anti-rabbit. Prepare colloidal gold test strips for detecting pirB antigen protein. Add 100 μL of pirB antigen protein samples with concentrations of 1 mg / mL, 0.5 mg / mL, 0.25 mg / mL, 125 μg / mL, 62.5 μg / mL, and 31.25 μg / mL to test strips No. 1-6, respectively, and add 100 μL of PBS to test strip No. 7 as a blank control. The specific colloidal gold test strip C line, T line, gold-labeled antibody combination and antigen concentration are shown in Table 10. Observe the line development after about 5-10 minutes.
[0219] Test case 7 results are as follows Fig.23 As shown, the color of the T line becomes lighter as the concentration of pirB antigen protein decreases, and the sensitivity is 62.5 μg / mL.
[0220] Table 10 The combination of C line, T line, gold-labeled antibody and antigen concentration in the sensitivity test of pirB antigen colloidal gold test strip
[0221] Serial number C-line antibodies T-line antibody Gold labeled antibody Sample concentration 1 Goat anti-rabbit VHH-B1 Rabbit polyclonal antibody 1mg / mL 2 Goat anti-rabbit VHH-B1 Rabbit polyclonal antibody 0.5mg / mL 3 Goat anti-rabbit VHH-B1 Rabbit polyclonal antibody 0.25mg / mL 4 Goat anti-rabbit VHH-B1 Rabbit polyclonal antibody 125 μg / mL 5 Goat anti-rabbit VHH-B1 Rabbit polyclonal antibody 62.5 μg / mL 6 Goat anti-rabbit VHH-B1 Rabbit polyclonal antibody 31.25 μg / mL 7 Goat anti-rabbit VHH-B1 Rabbit polyclonal antibody 0
[0222] Test Example 8 pirB antigen protein specific detection
[0223] Select the colloidal gold test strip combination No. 8 in test example 6, that is, the gold-labeled antibody is rabbit polyclonal antibody, the T-line antibody is VHH-B2, and the C-line antibody is goat anti-rabbit. Prepare colloidal gold test strips for detecting pirB antigen protein. Add 100 μL of 5 pathogenic proteins with a concentration of 1 mg / mL to test strips No. 1-5 respectively: pirB, MBP, GST, SWP1, VP28. Observe the line development after about 5-10 minutes.
[0224] Test case 8 results are as follows Fig.24 It shows that except for the test strip with pirB added, which has obvious T line and C line, the other test strips have only C line but no T line, which proves that the colloidal gold test strip No. 8 in test example 4 can specifically recognize the pirB antigen protein.
[0225] Test Example 9
[0226] Referring to Test Example 8, 100 μL of 1 mg / mL pathogenic protein was tested from the enriched shrimp culture water sample, and the colloidal gold test strips prepared by using the gold-labeled antibody as rabbit polyclonal antibody, the T-line antibody as VHH-B2, and the C-line antibody as goat anti-rabbit were used for detection, and the results were the same as Fig.24 The basically identical pirB antigen colloidal gold test strip specificity test result graph indicates that the shrimp farming water sample contains Vibrio parahaemolyticus.
[0227] Test Example 10
[0228] Referring to Test Example 8, 100 μL of 1 mg / mL pathogenic protein solution enriched with shrimp aquaculture feed was tested by using colloidal gold test strips prepared with rabbit polyclonal antibody, VHH-B2 as T-line antibody, and goat anti-rabbit as C-line antibody. Fig.24 The basically identical pirB antigen colloidal gold test strip specificity test result graph indicates that the shrimp farming feed contains Vibrio parahaemolyticus.
[0229] It can be concluded that the VHH nanoantibody provided by the present invention binds well to colloidal gold, and two antibody combinations are produced, wherein the first antibody combination is used to specifically identify the pirA antigen protein, including: a first gold-labeled antibody with an amino acid sequence of SEQ ID NO.9, a first T-line antibody with an amino acid sequence of SEQ ID NO.8, and an anti-his tag antibody as a first C-line antibody; the second antibody combination is used to specifically identify the pirB antigen protein, including: a rabbit polyclonal antibody as a second gold-labeled antibody, a second T-line antibody with an amino acid sequence of SEQ ID NO.11, and a goat anti-rabbit antibody as a second C-line antibody. The test strip prepared by the combination of the above two antibodies can specifically identify the pirA and pirB proteins of Vibrio parahaemolyticus. It can quickly detect whether aquatic animals such as shrimp are infected with Vibrio parahaemolyticus, whether the aquaculture water contains Vibrio parahaemolyticus, or whether the aquaculture feed and fresh bait are contaminated with Vibrio parahaemolyticus within 10 minutes, thereby solving the effective prevention and efficient monitoring of epidemics in shrimp farming production, laying the foundation for the rapid detection of Vibrio parahaemolyticus, and providing a reference model for the early detection of pathogens in other farmed animals. It has wide applicability.
[0230] The terms and expressions used herein are for descriptive purposes only and the present invention should not be limited to these terms and expressions. The use of these terms and expressions does not mean to exclude any equivalent features of the illustrations and descriptions (or parts thereof), and it should be recognized that various modifications that may exist should also be included in the scope of the claims. Other modifications, changes and substitutions may also exist. Accordingly, the claims should be deemed to cover all such equivalents.
[0231] Similarly, it should be pointed out that although the present invention has been described with reference to the current specific embodiments, ordinary technicians in this technical field should realize that the above embodiments are only used to illustrate the present invention, and various equivalent changes or substitutions may be made without departing from the spirit of the present invention. Therefore, as long as the changes and modifications to the above embodiments are within the scope of the essential spirit of the present invention, they will fall within the scope of the claims of the present invention.
Claims
1. A nanobody against pirA for detecting Vibrio parahaemolyticus, characterized in that The amino acid sequence of the anti-pirA nanobody is: SEQ ID NO.8, SEQ ID NO.9 or SEQ ID NO.
10.
2. A nanobody for detecting anti-pirB of Vibrio parahaemolyticus, characterized in that The amino acid sequence of the anti-pirB nanobody is: SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19 or SEQ ID NO.
20.
3. The Nanobody according to claim 1 or 2, characterized in that The Vibrio parahaemolyticus is a specific virulent strain Vp AHPND .
4. The Nanobody according to claim 1 or 2, characterized in that The nanobody is of alpaca or camel origin.
5. Use of the Nanobody as described in claim 1 or 2 in the detection of Vibrio parahaemolyticus for non-diagnostic purposes.
6. A Vibrio parahaemolyticus detection product comprising the nanobody according to claim 1 or 2.
7. The Vibrio parahaemolyticus detection product according to claim 6, characterized in that: The Vibrio parahaemolyticus detection product comprises a reagent, a test strip or a test kit, wherein the test strip comprises an immunochromatographic test strip prepared by using any one of the labeling technologies of colloidal gold labeling, colloidal carbon labeling, fluorescent microsphere labeling and nanoparticle labeling.
8. The Vibrio parahaemolyticus detection product according to claim 6, characterized in that: The Vibrio parahaemolyticus detection product includes a first antibody combination and a second antibody combination; the first antibody combination is used to specifically identify the pirA antigen protein, including: a first gold-labeled antibody with an amino acid sequence of SEQ ID NO.9, a first T-line antibody with an amino acid sequence of SEQ ID NO.8, and an anti-his tag antibody as a first C-line antibody; the second antibody combination is used to specifically identify the pirB antigen protein, including: a rabbit polyclonal antibody as a second gold-labeled antibody, a second T-line antibody with an amino acid sequence of SEQ ID NO.11, and a goat anti-rabbit antibody as a second C-line antibody.
